Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Immunology Letters|February 28, 2016
A critical role for the protein kinase PKK in the maintenance of recirculating mature B cells and the development of B1 cellsLuojing Chen, David Oleksyn, Mary Pulvino, et al.
The Journal of Rheumatology|July 15, 2024
GRAPPA 2023 Collaborative Research Network MeetingVinod Chandran, Dafna D Gladman, Philip J Mease, et al.
The Journal of Investigative Dermatology|July 25, 2021
New Frontiers in Psoriatic Disease Research, Part I: Genetics, Environmental Triggers, Immunology, Pathophysiology, and Precision MedicineDi Yan, Johann E Gudjonsson, Stephanie Le, et al.
Rheumatology (Oxford, England)|February 11, 2024
Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritisDennis McGonagle, Arthur Kavanaugh, Iain B McInnes, et al.
Arthritis Care & Research|June 23, 2015
Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III TrialArthur Kavanaugh, Lluís Puig, Alice B Gottlieb, et al.
RMD Open|January 16, 2021
Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritisJon T Giles, Alexis Ogdie, Juan J Gomez Reino, et al.
Lancet (London, England)|June 18, 2013
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trialIain B McInnes, Arthur Kavanaugh, Alice B Gottlieb, et al.
Seminars in Arthritis and Rheumatism|September 19, 2024
Utility of factor D and other alternative complement factors as biomarkers in systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH)Eva Petrow, Changyong Feng, Ashley Frazer-Abel, et al.
Annals of the Rheumatic Diseases|February 21, 2014
Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trialsArthur Kavanaugh, Christopher Ritchlin, Proton Rahman, et al.
Arthritis Research & Therapy|December 28, 2022
Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritisPhilip Mease, Désirée van der Heijde, Bruce Kirkham, et al.
Pageof 7